Meloxicam

Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Meloxicam Oral Suspension

Meloxisol™ Injection is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Meloxisol™

Indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Do not administer a second dose of meloxicam. Do not follow the single, one-time dose of meloxicam with any other NSAID. Do not administer meloxicam oral suspension following the single, one-time injectable dose of meloxicam.

Loxicom®

For the control of pain and inflammation associated with osteoarthritis in dogs.

For oral use in dogs only. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer meloxicam transmucosal oral spray to cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

OroCAM® Transmucosal Oral Spray

For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration when administered prior to surgery.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.

Metacam® 5 mg/mL Solution for Injection

Indications: Cats: For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Dogs: OstiLoxTM (meloxicam) 5 mg/mL Solution for Injection is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

OstiLox™ (meloxicam) 5 mg/mL Solution for Injection

Indications: Meloxidyl Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Indications: Dogs: Meloxivet Injection is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

For the control of pain and inflammation associated with osteoarthritis in dogs

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Meloxidyl®

Clinical Pharmacology: Meloxicam has nearly 100% bioavailability when administered orally or after subcutaneous injection in dogs. The terminal elimination half-life after a single dose is estimated to be approximately 24 hrs (+/- 30%) in dogs regardless of route of administration. Drug bioavailability, volume of distribution, and total systemic clearance remain constant up to 5 times the recommended dose for use in dogs. However, there is some evidence of enhanced drug accumulation and terminal elimination half-life prolongation when dogs are dosed for 45 days or longer. Peak drug concentrations of 0.734 mcg/mL can be expected to occur within 2.5 hours following a 0.2 mg/kg subcutaneous injection in dogs. Based upon intravenous administration in Beagle dogs, the meloxicam volume of distribution in dogs (Vdλ) is approximately 0.32 L/kg and the total systemic clearance is 0.01 L/hr/kg. The drug is 97% bound to canine plasma proteins.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Clinical Pharmacology: Meloxicam has nearly 100% bioavailability when administered orally with food. The terminal elimination half life after a single dose is estimated to be approximately 24 hrs (+/- 30%) regardless of route of administration. There is no evidence of statistically significant gender differences in drug pharmacokinetics. Drug bioavailability, volume of distribution, and total systemic clearance remain constant up to 5 times the recommended dose for use in dogs. However, there is some evidence of enhanced drug accumulation and terminal elimination half-life prolongation when dogs are dosed for 45 days or longer. Peak drug concentrations can be expected to occur within about 7.5 hrs after oral administration. Corresponding peak concentration is approximately 0.464 mcg/mL following a 0.2 mg/kg oral dose. The drug is 97% bound to canine plasma proteins.

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Clinical Pharmacology: Meloxicam has nearly 100% bioavailability after subcutaneous injection in cats. The terminal elimination half life after a single dose is estimated to be approximately 15 hrs (+/-10%) in cats. Peak drug concentrations of 1.1 mcg/mL can be expected to occur within 1.5 hours following a 0.3 mg/kg subcutaneous injection in cats. The volume of distribution (Vdλ) in cats is approximately 0.27 L/kg, with an estimated total systemic clearance of 0.013 L/hr/kg. The drug is 97% bound to feline plasma proteins.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Dogs with known hypersensitivity to meloxicam should not receive Meloxicam oral suspension. Do not use Meloxicam oral suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Shake bottle well. Push down and unscrew bottle top. Attach the dosing syringe to the bottle by gently pushing onto the top of the bottle. Turn the bottle/syringe upside down. Pull the plunger out until the medication level corresponds to the dog's body weight in pounds. Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle. Push the plunger to empty the contents of the syringe.

covetrus® Professional Insert

Cats with known hypersensitivity to meloxicam should not receive meloxicam injection 5 mg/mL solution for injection. Additional doses of meloxicam or other NSAIDs in cats are contraindicated, as no safe dosage for repeated NSAID administration has been established (See Animal Safety). Do not use meloxicam in cats with pre-existing renal dysfunction.

covetrus®

Contraindications: Cats with known hypersensitivity to meloxicam should not receive Meloxivet Injection. Additional doses of meloxicam or other NSAIDs in cats are contraindicated, as no safe dosage for repeated NSAID administration has been established (See Animal Safety). Do not use meloxicam in cats with pre-existing renal dysfunction.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Meloxidyl Oral Suspension. Do not use Meloxidyl Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Dogs with known hypersensitivity to meloxicam should not receive Loxicom Oral Suspension. Do not use Loxicom Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Professional Insert

Dogs with known hypersensitivity to meloxicam should not receive meloxicam injection 5 mg/mL solution for injection.

covetrus®

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Meloxivet Injection.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Dogs with known hypersensitivity to meloxicam should not receive Meloxicam Injection.

Meloxicam 5 mg/mL Solution for Injection

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For subcutaneous (SQ) injectable use in cats. Do not use IV in cats. Do not administer a second dose of meloxicam. Do not follow the single, one-time dose of meloxicam with any other NSAID. Do not administer meloxicam oral suspension following the single, one-time injectable dose of meloxicam. When administering any NSAID, appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to use in dogs and cats. All cats should undergo a thorough history and physical examination before administering meloxicam. Do not repeat the single, one-time dose of meloxicam in cats. Owner should be advised to observe their cats for signs of potential drug toxicity.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and begiven a client information sheet about OstiLox (meloxicam) Oral Suspension. Keep OstiLox (meloxicam) Oral Suspension in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion or overdose.

OstiLoxTM (meloxicam) Oral Suspension 1.5 mg/mL (equivalent to 0.05 mg per drop) Non-steroidal anti-inflammatory drug for oral use in dogs only

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about Meloxidyl Oral Suspension. Keep Meloxidyl in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about Loxicom.

Professional Insert

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For IV or SQ injectable use in dogs. All dogs should undergo a thorough history and physical examination before administering any NSAID. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to, and periodically during use of any NSAID in dogs. Owner should be advised to observe their dogs for signs of potential drug toxicity.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Cats: A field study involving 138 cats was conducted. Of the 72 cats receiving meloxicam injection, six cats (8.3%) experienced post-treatment elevated serum blood urea nitrogen (BUN) levels. The pre-treatment values were in the normal range. Of the 66 cats in the butorphanol treatment group, no cats experienced post-treatment elevated serum blood urea nitrogen levels. Nine cats (12.5%) receiving meloxicam Injection had post-treatment anemia. Pre-treatment, these cats all had hematocrit and hemoglobin values in the normal range. Four cats (6.1%) in the butorphanol treatment group had post-treatment anemia. All but one cat, who had a mild anemia pre-treatment (hematocrit = 21% and hemoglobin = 7.0 g/dL) had normal pre-treatment values. Twenty-four hours after the injection with meloxicam injection, one cat experienced pain upon palpation of the injection site. Foreign Experience: Repeated use in cats has been associated with acute renal failure and death. In studies used for the foreign approval of meloxicam injection in cats, lethargy, vomiting, inappetence, and transient pain immediately after injection were noted. Diarrhea and fecal occult blood have also been reported. Post-Approval Experience (Rev. 2009): The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system: Urinary: azotemia, elevated creatine, elevated phosphorus, renal failure Gastrointestinal: anorexia, vomiting, diarrhea Neurologic/Behavioral: lethargy, depression Hematologic: anemia Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats. CONTACT INFORMATION: To report suspected adverse drug events, for technical assistance, or to obtain a copy of the SDS, contact Covetrus® North America at (855) 724-3461or covetrus.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae

Meloxicam Injection 5 mg/mL Solution for Injection

Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). Post-Approval Experience (Rev. 2010): The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system. Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes Dermatologic: pruritus Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

Metacam® (meloxicam oral suspension) 1.5 mg/mL

Dogs: A field study involving 224 dogs was conducted. Based on the results of this study, GI abnormalities (vomiting, soft stools, diarrhea, and inappetance) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the study. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting, adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). Post-Approval Experience (Rev. 2009): The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system: Gastrointestinal: vomiting, diarrhea, melena, gastrointestinal ulceration Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes Dermatologic: pruritus Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Boehringer Ingelheim Animal Health USA Inc.,1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

Metacam® (meloxicam) 5 mg/mL Solution for Injection

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system. Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes Dermatologic: pruritus Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

Metacam® (meloxicam oral suspension)0.5 mg/mL

Adverse Reactions: Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). Adverse Reactions Observed During Two Field Studies Clinical Observation Meloxicam (n = 157) Placebo (n = 149) Vomiting 40 23 Diarrhea/Soft Stool 19 11 Bloody Stool 1 0 Inappetance 5 1 Bleeding Gums After Dental Procedure 1 0 Lethargy/Swollen Carpus 1 0 Epiphora 1 0

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetance) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. Adverse Reactions Observed During Two Field Studies Clinical Observation Meloxicam (n=157) Placebo (n=149) Vomiting 40 23 Diarrhea/Soft Stool 19 11 Bloody Stool 1 0 Inappetance 5 1 Bleeding gums after dental procedure 1 0 Lethargy/Swollen Carpus 1 0 Epiphora 1 0 In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

Professional Insert

Adverse Reactions: Dogs: A field study involving 224 dogs was conducted. Based on the results of this study, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the study. Dogs may have experienced more than one episode of the adverse reaction during the study. Adverse Reactions Observed During Field Study Clinical Observation Meloxicam (n = 109) Placebo (n = 115) Vomiting 31 15 Diarrhea/Soft Stool 15 11 Inappetence 3 0 Bloody Stool 1 0 In foreign suspected adverse drug reaction (SADR) reporting, adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Adverse Reactions: Cats: A field study involving 138 cats was conducted. Of the 72 cats receiving meloxicam injection, six cats (8.3%) experienced post-treatment elevated serum blood urea nitrogen (BUN) levels. The pre-treatment values were in the normal range. Of the 66 cats in the butorphanol treatment group, no cats experienced post-treatment elevated serum blood urea nitrogen levels. Nine cats (12.5%) receiving meloxicam Injection had post-treatment anemia. Pre-treatment, these cats all had hematocrit and hemoglobin values in the normal range. Four cats (6.1%) in the butorphanol treatment group had post-treatment anemia. All but one cat, who had a mild anemia pre-treatment (hematocrit=21% and hemoglobin=7.0 g/dL) had normal pre-treatment values. Twenty-four hours after the injection with meloxicam injection, one cat experienced pain upon palpation of the injection site.

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system: Urinary: azotemia, elevated creatinine, elevated phosphorus, renal failure Gastrointestinal: anorexia, vomiting, diarrhea Neurologic/Behavioral: lethargy, depression Hematologic: anemia Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Boehringer Ingelheim Animal Health USA Inc., 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae .

Metacam® (meloxicam) 5 mg/mL Solution for Injection

Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

Metacam® (meloxicam oral suspension)0.5 mg/mL

Repeated use in cats has been associated with acute renal failure and death. In studies used for the foreign approval of METACAM Injection in cats, lethargy, vomiting, inappetance, and transient pain immediately after injection were noted. Diarrhea and fecal occult blood have also been reported.

Metacam® (meloxicam) 5 mg/mL Solution for Injection

Meloxicam Solution for Injection should be administered initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth

Intravenous, Subcutaneous

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Meloxicam Solution for Injection

Administer initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.

Subcutaneous, Intravenous

Meloxicam Injection

Administer 0.09 mg per pound (0.2 milligram per kilogram) body weight by intravenous or subcutaneous injection on the first day of treatment. For treatment after day 1, administer meloxicam suspension orally at 0.045 mg/lb (0.1 milligram per kilogram) body weight once daily.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Metacam® 5 mg/mL Solution for Injection

Administer 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) by intravenous or subcutaneous injection on the first day of treatment. For treatment after day 1, administer meloxicam suspension orally at 0.045 mg/lb (0.1 mg/kg) body weight once daily.

Intravenous, Subcutaneous

Meloxisol™

Administer orally as a single dose at 0.09 mg per pound body weight (0.2 milligram per kilogram) on the first day of treatment. For all treatment after day 1, administer 0.045 milligram per pound (0.1 milligram per kilogram) body weight once daily.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For oral use in dogs only. Do not use in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Metacam® Oral Suspension

Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.

Oral

Meloxisol™

On the first day of treatment, administer 0.09 mg/lb (0.2 mg/kg). For all treatments after day 1, administer once daily at a dose of 0.045 mg/lb (0.1 mg/ kg).

Oral

For oral use in dogs only.

Loxicom®

Administer 0.1 mg per kilogram of body weight once daily using the metered dose pump.

Oral

For oral use in dogs only. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer meloxicam transmucosal oral spray to cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

OroCAM® Transmucosal Oral Spray

Administer a single, one-time subcutaneous dose of Meloxicam injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended.

Intravenous, Subcutaneous

Meloxicam

Administer a single, one-time subcutaneous dose of Meloxicam Solution for Injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated

Intravenous, Subcutaneous

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Meloxicam Solution for Injection

Administer a single, one-time subcutaneous dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated.

Subcutaneous, Intravenous

Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.

Meloxicam Injection

Administer 0.14 mg/lb (0.3 milligram per kilogram) body weight as a single, one-time subcutaneous injection.

Subcutaneous, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.

Metacam® 5 mg/mL Solution for Injection

Administer a single, one-time subcutaneous dose to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight.

Intravenous, Subcutaneous

Do not administer a second dose of meloxicam. Do not follow the single, one-time dose of meloxicam with any other NSAID. Do not administer meloxicam oral suspension following the single, one-time injectable dose of meloxicam.

Loxicom®

Dogs under 10 pounds (4.5 kg) Shake well before use, then remove cap. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, administer drops on food only, never directly into the mouth. Carefully measure suspension onto food to assure that the correct dose is given before presentation of the food to the dog. The syringe provided with the meloxicam concentration of 0.5 mg/mL cannot be used to measure doses for dogs weighing less than 2 lbs (0.90 kg). For dogs less than 2 lbs (0.90 kg), METACAM Oral Suspension can be given using the dropper bottle: two drops for each pound of body weight for the 0.5 mg/mL concentration (five drops for each kilogram of body weight), dropped directly onto the food. For dogs between 2 - 10 pounds, METACAM Oral Suspension can be given by drops or by using the measuring syringe provided in the package (see dosing procedure in the next column). The syringe fits on to the bottle and has a scale beginning at 2 lbs, designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 1 pound increment. Replace and tighten cap after use. Dogs over 10 pounds (4.5 kg) Shake well before use then remove cap. METACAM Oral Suspension may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. METACAM Oral Suspension can be given using the measuring syringe provided in the package (see dosing procedure in the next column). The syringe fits on to the bottle and has a scale in pounds designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 1 pound increment. Alternatively, METACAM Oral Suspension can be given using the dropper bottle: two drops for each pound of body weight for the 0.5 mg/mL concentration (five drops for each kilogram of body weight). Replace and tighten cap after use.

ORAL

Metacam® (meloxicam oral suspension)0.5 mg/mL

Dogs under 10 pounds (4.5 kg) Shake well before use, then remove cap. Particular care should be given with regard to the accuracy of dosing. To prevent accidental overdosing of small dogs, administer drops on food only, never directly into the mouth. Carefully measure suspension onto food to assure that the correct dose is given before presentation of the food to the dog. The syringe provided with the meloxicam concentration of 1.5 mg/mL cannot be used to measure doses for dogs weighing less than 5 lbs (2.3 kg). For dogs less than 5 lbs (2.3 kg), METACAM Oral Suspension can be given using the dropper bottle: one drop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight), dropped directly onto the food. For dogs between 5 - 10 pounds, METACAM Oral Suspension can be given by drops or by using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale beginning at 5 lbs, designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 5 pound increment. Replace and tighten cap after use. Dogs over 10 pounds (4.5 kg) Shake well before use then remove cap. METACAM Oral Suspension may be either mixed with food or placed directly into the mouth. Particular care should be given with regard to the accuracy of dosing. METACAM Oral Suspension can be given using the measuring syringe provided in the package (see dosing procedure below). The syringe fits on to the bottle and has a scale in pounds designed to deliver the daily maintenance dose (0.05 mg/lb or 0.1 mg/kg). When using the syringe, the dog’s weight should be rounded down to the nearest 5 pound increment. Alternatively, METACAM Oral Suspension can be given using the dropper bottle: one drop for each pound of body weight for the 1.5 mg/mL concentration (two drops for each kilogram of body weight). Replace and tighten cap after use.

ORAL

Metacam® (meloxicam oral suspension) 1.5 mg/mL

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of Loxicom Oral Suspension and other treatment options before deciding to use Loxicom Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. Loxicom Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Loxicom Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The syringes are calibrated to deliver the daily maintenance dose in lbs. Because the first dose (0.2 mg/kg) is two times the amount of the daily maintenance dose (0.1 mg/kg), two syringes containing the 0.1 mg/kg dose should be administered at the first dose.

ORAL

Professional Insert

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of OstiLox Oral Suspension and other treatment options before deciding to use OstiLox Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. OstiLox Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, OstiLox Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The syringes are calibrated to deliver the daily maintenance dose in lbs. Because the first dose (0.2 mg/kg) is two times the amount of the daily maintenance dose (0.1 mg/kg), two syringes containing the 0.1 mg/kg dose should be administered at the first dose.

ORAL

Professional Insert

Dosage and Administration: Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of Meloxidyl Oral Suspension and other treatment options before deciding to use Meloxidyl Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. Meloxidyl Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Meloxidyl Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The syringes are calibrated to deliver the daily maintenance dose in lbs. The daily dose (0.045 mg/lb) contains 0.03 mL of Meloxidyl Oral Suspension for every 1 lb (0.45 kg) of dog body weight.

ORAL

Meloxidyl® (meloxicam oral suspension) 1.5 mg/mL

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk ofOstiLox(meloxicam) Oral Suspension and other treatment options before deciding to use OstiLox (meloxicam) Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. OstiLox (meloxicam) Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, OstiLox (meloxicam) Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg).The syringe is calibrated to deliver the daily maintenance dose in pounds.

ORAL

OstiLoxTM (meloxicam) Oral Suspension 1.5 mg/mL (equivalent to 0.05 mg per drop) Non-steroidal anti-inflammatory drug for oral use in dogs only

Always provide client information sheet with prescription. Carefully consider the potential benefits and risks of Meloxicam oral suspension and other treatment options before deciding to use Meloxicam oral suspension. Use the lowest effective dose for the shortest duration consistent with individual response. Meloxicam oral suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Meloxicam oral suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The provided syringes are calibrated to deliver the daily maintenance dose in pounds.

ORAL

covetrus® Professional Insert

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of Meloxicam Oral Suspension and other treatment options before deciding to use Meloxicam Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. Meloxicam Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Meloxicam Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The syringe is calibrated to deliver the daily maintenance dose in pounds.

ORAL

Meloxicam Oral Suspension 1.5 mg/mL (equivalent to 0.05 mg per drop) Non-steroidal anti-inflammatory drug for oral use in dogs only

Always provide client information sheet with prescription. Carefully consider the potential benefits and risks of OstiLox and other treatment options before deciding to use OstiLox. Use the lowest effective dose for the shortest duration consistent with individual response. OstiLox oral suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, OstiLox oral suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The provided syringes are calibrated to deliver the daily maintenance dose in pounds.

ORAL

Professional Insert

Always provide client information sheet with prescription. Carefully consider the potential benefits and risks of Loxicom and other treatment options before deciding to use Loxicom. Use the lowest effective dose for the shortest duration consistent with individual response. Loxicom oral suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, Loxicom oral suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The provided syringes are calibrated to deliver the daily maintenance dose in pounds.

ORAL

Professional Insert

Carefully consider the potential benefits and risk of OstiLox and other treatment options before deciding to use OstiLoxTM (meloxicam) 5 mg/mL Solution for Injection. Use the lowest effective dose for the shortest duration consistent with individual response. Dogs: OstiLox (meloxicam) 5 mg/mL Solution for Injection should be administered initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.

SUBCUTANEOUS, INTRAVENOUS

OstiLox™ (meloxicam) 5 mg/mL Solution for Injection

Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of METACAM and other treatment options before deciding to use METACAM. Use the lowest effective dose for the shortest duration consistent with individual response. METACAM Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, METACAM Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/kg). The syringe is calibrated to deliver the daily maintenance dose in pounds.

ORAL

Metacam® (meloxicam oral suspension) 1.5 mg/mL

Carefully consider the potential benefits and risk of meloxicam injection and other treatment options before deciding to use meloxicam injection. Use the lowest effective dose for the shortest duration consistent with individual response. Dogs: Meloxicam injection 5 mg/mL solution for injection should be administered initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.

INTRAVENOUS, SUBCUTANEOUS

covetrus®

Carefully consider the potential benefits and risk of OstiLox and other treatment options before deciding to use OstiLox 5 mg/mL Solution for Injection. Use the lowest effective dose for the shortest duration consistent with individual response. Cats: Administer a single, one-time subcutaneous dose of OstiLoxTM (meloxicam) 5 mg/mL Solution for Injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. (See Contraindications). To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended.

SUBCUTANEOUS, INTRAVENOUS

OstiLox™ (meloxicam) 5 mg/mL Solution for Injection

Administer orally as a single dose at 0.09 mg per pound body weight (0.2 milligram per kilogram) on the first day of treatment. For all treatment after day 1, administer 0.045 milligram per pound (0.1 milligram per kilogram) body weight once daily.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Meloxidyl®

Dosage and Administration: Carefully consider the potential benefits and risk of Meloxivet and other treatment options before deciding to use Meloxivet. Use the lowest effective dose for the shortest duration consistent with individual response.

INTRAVENOUS, SUBCUTANEOUS

Meloxivet™ (meloxicam) 5 mg/mL Solution for Injection

Carefully consider the potential benefits and risk of meloxicam injection and other treatment options before deciding to use meloxicam injection. Use the lowest effective dose for the shortest duration consistent with individual response.

INTRAVENOUS, SUBCUTANEOUS

covetrus®